|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000166086 |
Summary for JAM3 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000166086 | Gene symbol | JAM3 |
| Gene name | junctional adhesion molecule 3 | |
| HGNC | 15532 | |
| Entrez ID | 83700 | |
| Gene type | protein_coding | |
| Synonyms | JAM3|JAM-C|JAMC | |
| UniProtAcc | Q9BX67 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for JAM3 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| JAM3 | 1.67e+03 | -1.03e+00 | 2.69e-01 | -3.83e+00 | 1.29e-04 | 2.94e-02 | KICH |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| JAM3 | 6.90e+02 | -1.40e+00 | 2.72e-01 | -5.14e+00 | 2.69e-07 | 1.05e-06 | KIRP |
| JAM3 | 1.29e+03 | -1.44e+00 | 3.66e-01 | -3.93e+00 | 8.60e-05 | 8.91e-04 | ESCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| JAM3 | 1.11e+03 | -1.40e+00 | 1.40e-01 | -9.99e+00 | 1.62e-23 | 2.73e-22 | LUAD |
| JAM3 | 1.72e+03 | -1.14e+00 | 8.14e-02 | -1.40e+01 | 2.00e-44 | 1.69e-43 | BRCA |
| JAM3 | 6.37e+02 | -2.01e+00 | 3.43e-01 | -5.85e+00 | 4.98e-09 | 8.54e-08 | READ |
Top |
Sex-biased somatic mutation for JAM3 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for JAM3 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg24899571 | chr11:134068915 | CGI:chr11:134068955-134069786 | promoter | 1.43e-01 | 2.29e-02 | 4.85e+00 | 1.25e-06 | 4.40e-06 | 1.20e-01 |
| THCA | cg04913265 | chr11:134069732 | CGI:chr11:134068955-134069786 | promoter,gene body | 3.52e-01 | 2.30e-01 | 2.58e+00 | 9.83e-03 | 1.63e-02 | 1.22e-01 |
| HNSC | cg24899571 | chr11:134068915 | CGI:chr11:134068955-134069786 | promoter | 1.71e-01 | 3.42e-02 | 3.52e+00 | 4.37e-04 | 8.99e-04 | 1.37e-01 |
| HNSC | cg14962363 | chr11:134069370 | CGI:chr11:134068955-134069786 | promoter,gene body | 1.31e-01 | 1.83e-02 | 5.36e+00 | 8.40e-08 | 8.49e-07 | 1.12e-01 |
| HNSC | cg24140030 | chr11:134068862 | CGI:chr11:134068955-134069786 | promoter | 2.10e-01 | 7.64e-02 | 3.32e+00 | 8.88e-04 | 1.64e-03 | 1.34e-01 |
| HNSC | cg24625128 | chr11:134069169 | CGI:chr11:134068955-134069786 | promoter,gene body | 2.41e-01 | 6.24e-02 | 3.55e+00 | 3.89e-04 | 8.14e-04 | 1.79e-01 |
| HNSC | cg07545846 | chr11:134070625 | CGI:chr11:134068955-134069786 | promoter,gene body | 6.41e-01 | 7.43e-01 | -2.00e+00 | 4.56e-02 | 4.63e-02 | -1.01e-01 |
| LUSC | cg04913265 | chr11:134069732 | CGI:chr11:134068955-134069786 | promoter,gene body | 4.83e-01 | 3.22e-01 | 3.09e+00 | 1.97e-03 | 4.14e-03 | 1.61e-01 |
| LUSC | cg07545846 | chr11:134070625 | CGI:chr11:134068955-134069786 | promoter,gene body | 5.84e-01 | 7.33e-01 | -2.11e+00 | 3.53e-02 | 3.76e-02 | -1.50e-01 |
| COAD | cg19055936 | chr11:134068781 | CGI:chr11:134068955-134069786 | promoter | 2.55e-01 | 1.29e-01 | 2.59e+00 | 9.47e-03 | 1.38e-02 | 1.26e-01 |
| BLCA | cg02174225 | chr11:134069046 | CGI:chr11:134068955-134069786 | UTR,promoter,exon,gene body | 1.44e-01 | 2.28e-02 | 2.12e+00 | 3.39e-02 | 3.70e-02 | 1.22e-01 |
| BLCA | cg03637878 | chr11:134068893 | CGI:chr11:134068955-134069786 | promoter | 1.78e-01 | 2.63e-02 | 3.06e+00 | 2.18e-03 | 4.20e-03 | 1.52e-01 |
| BLCA | cg04913265 | chr11:134069732 | CGI:chr11:134068955-134069786 | promoter,gene body | 5.28e-01 | 3.10e-01 | 3.63e+00 | 2.83e-04 | 8.59e-04 | 2.18e-01 |
| LIHC | cg03637878 | chr11:134068893 | CGI:chr11:134068955-134069786 | promoter | 1.93e-01 | 4.49e-02 | 2.04e+00 | 4.17e-02 | 4.26e-02 | 1.48e-01 |
| LIHC | cg08332071 | chr11:134067598 | CGI:chr11:134068955-134069786 | promoter | 6.17e-01 | 7.69e-01 | -3.55e+00 | 3.80e-04 | 6.71e-04 | -1.52e-01 |
| ESCA | cg04913265 | chr11:134069732 | CGI:chr11:134068955-134069786 | promoter,gene body | 5.90e-01 | 3.81e-01 | 2.52e+00 | 1.17e-02 | 3.69e-02 | 2.09e-01 |
| CHOL | cg02174225 | chr11:134069046 | CGI:chr11:134068955-134069786 | UTR,promoter,exon,gene body | 1.76e-01 | 1.95e-02 | 2.29e+00 | 2.23e-02 | 3.24e-02 | 1.56e-01 |
| CHOL | cg14962363 | chr11:134069370 | CGI:chr11:134068955-134069786 | promoter,gene body | 1.62e-01 | 2.25e-02 | 2.21e+00 | 2.70e-02 | 3.50e-02 | 1.39e-01 |
| CHOL | cg04913265 | chr11:134069732 | CGI:chr11:134068955-134069786 | promoter,gene body | 5.93e-01 | 2.90e-01 | 3.10e+00 | 1.96e-03 | 1.07e-02 | 3.03e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg02174225 | chr11:134069046 | CGI:chr11:134068955-134069786 | UTR,promoter,exon,gene body | 1.89e-01 | 2.07e-02 | 1.11e+01 | 1.23e-28 | 1.53e-27 | 1.69e-01 |
| BRCA | cg03637878 | chr11:134068893 | CGI:chr11:134068955-134069786 | promoter | 3.15e-01 | 3.26e-02 | 1.14e+01 | 6.15e-30 | 8.89e-29 | 2.82e-01 |
| BRCA | cg24899571 | chr11:134068915 | CGI:chr11:134068955-134069786 | promoter | 2.81e-01 | 3.37e-02 | 1.02e+01 | 1.38e-24 | 1.13e-23 | 2.47e-01 |
| BRCA | cg14962363 | chr11:134069370 | CGI:chr11:134068955-134069786 | promoter,gene body | 1.65e-01 | 2.30e-02 | 9.97e+00 | 2.02e-23 | 1.48e-22 | 1.42e-01 |
| BRCA | cg08332071 | chr11:134067598 | CGI:chr11:134068955-134069786 | promoter | 6.61e-01 | 9.10e-01 | -1.12e+01 | 6.12e-29 | 7.87e-28 | -2.49e-01 |
| BRCA | cg19055936 | chr11:134068781 | CGI:chr11:134068955-134069786 | promoter | 3.01e-01 | 1.07e-01 | 9.07e+00 | 1.18e-19 | 6.21e-19 | 1.94e-01 |
| BRCA | cg24140030 | chr11:134068862 | CGI:chr11:134068955-134069786 | promoter | 2.58e-01 | 5.96e-02 | 1.05e+01 | 7.69e-26 | 7.09e-25 | 1.98e-01 |
| BRCA | cg24625128 | chr11:134069169 | CGI:chr11:134068955-134069786 | promoter,gene body | 2.50e-01 | 4.17e-02 | 1.09e+01 | 1.66e-27 | 1.81e-26 | 2.08e-01 |
| BRCA | cg04913265 | chr11:134069732 | CGI:chr11:134068955-134069786 | promoter,gene body | 5.36e-01 | 2.39e-01 | 1.31e+01 | 1.90e-39 | 1.30e-37 | 2.98e-01 |
Top |
Exon skipping events with PSI in TCGA for JAM3 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for JAM3 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for JAM3 |
| TFs related to JAM3. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| JAM3 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for JAM3 |
| RBPs related to ES in JAM3. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| JAM3 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000166086 | TEX41,hsa-mir-340,JAM3 | Male-specific ceRNA | TCGA-KIRP |
| ENSG00000166086 | MIR133A1HG,hsa-mir-340,JAM3 | Male-specific ceRNA | TCGA-KIRP |
| ENSG00000166086 | LINC01915,hsa-mir-340,JAM3 | Male-specific ceRNA | TCGA-KIRP |
| ENSG00000166086 | AC008771.1,hsa-mir-340,JAM3 | Male-specific ceRNA | TCGA-KIRP |
| ENSG00000166086 | TGFB2-AS1,hsa-mir-340,JAM3 | Male-specific ceRNA | TCGA-KIRP |
| ENSG00000166086 | MAP4K3-DT,hsa-mir-340,JAM3 | Male-specific ceRNA | TCGA-KIRP |
| ENSG00000166086 | LINC02197,hsa-mir-495,JAM3 | Female-specific ceRNA | TCGA-LUAD |
| ENSG00000166086 | LINC01470,hsa-mir-495,JAM3 | Female-specific ceRNA | TCGA-LUAD |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs588107 | chr11:126610246:A:G | - | 0.0421226176801469 | 0.0320361310614634 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs1939720 | chr11:134691677:T:A | - | 0.255288856538575 | 0.0271852302328965 | READ | Male-baised eQTL |
| rs2659598 | chr11:132886006:A:T | - | 0.156565134466366 | 0.000679982302646348 | LGG | Male-baised eQTL |
| rs7128043 | chr11:124646114:G:C | - | 0.0785494816125598 | 0.0240719083660629 | KIRC | Male-baised eQTL |
| rs11607996 | chr11:131451823:G:T | - | 0.0598718974065283 | 0.0245491485329871 | BLCA | Male-baised eQTL |
| rs11222621 | chr11:131450583:G:C | - | 0.0555883793160766 | 0.0348441677715687 | BLCA | Male-baised eQTL |
| rs11603217 | chr11:131450767:A:G | - | 0.0516216119708184 | 0.0480399566545988 | BLCA | Male-baised eQTL |
| rs1647967 | chr11:131073786:G:A | - | 0.0821256104298896 | 0.00723783678691607 | COAD | Male-baised eQTL |
| rs1030346 | chr11:131070702:A:T | - | 0.075407813695425 | 0.0149542797031779 | COAD | Male-baised eQTL |
| rs470459 | chr11:134139014:T:C | gene | -0.0579359124755719 | 0.0248466927758019 | COAD | Male-baised eQTL |
| rs1946088 | chr11:126750894:T:A | - | 0.102572101678885 | 0.036042066030217 | COAD | Male-baised eQTL |
| rs12576579 | chr11:124562828:G:C | - | 0.0591594973414171 | 0.0360849233624169 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000166086 |
| CpG Site: cg08332071 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.422612999304864 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg08332071 | chr11:134067598 | promoter | -0.422612999304864 | 3.97819922772385e-09 | -0.4230400438815899 | 1.7098976717130838e-12 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of JAM3 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000166086 | JAM3 | C3151000 | HEMORRHAGIC DESTRUCTION OF THE BRAIN, SUBEPENDYMAL CALCIFICATION, AND CATARACTS | 1 | CTD_human |
